ANTITUMOR AGENT AND ANTITUMOR EFFECT AMPLIFIER Russian patent published in 2022 - IPC A61K31/47 A61K39/395 A61P35/00 

FIELD: medicine.

SUBSTANCE: invention relates to a method for the treatment of tumor, including joint administration of a compound of acylthiourea or its pharmaceutically acceptable salt and a regulator of molecules of control points of an immune response, selected from an antagonist of PD-1 metabolism path and an antagonist of CTLA-4 metabolism path, such as nivolumab, pembrolizumab, atezolizumab, and ipilimumab. The compound of acylthiourea is 4-(2-fluor-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide, and its daily dose is from 25 to 100% of a dose recommended in separate administration of the compound of acylthiourea or its salt, where the recommended dose for human of the compound of acylthiourea or its salt is from 100 to 1200 mg/patient/day. A nivolumab dose is 0.3-3 mg/kg of the body weight per administration; a pembrolizumab dose is 0.2-2 mg/kg (of the body weight) or 20-200 mg per administration; an atezolizumab dose is 120-1200 mg per administration, and an ipilimumab dose is 0.3-3 mg/kg (of the body weight) per administration. The invention also relates to a method for enhancing an antitumor effect, to a method for prevention and/or treatment of cancer, including administration of therapeutically or prophylactically effective amount of nivolumab, pembrolizumab, atezolizumab, or ipilimumab to a patient suffering from cancer and a compound of acylthiourea, as well as to a combined antitumor agent.

EFFECT: invention provides a stronger antitumor effect without serious side effects compared to the use of compounds in separate.

24 cl, 2 dwg, 4 tbl, 6 ex